Latest Information Update: 24 Jan 2007
At a glance
- Originator Pfizer
- Class Antiarrhythmics; Benzofurans; Pyrrolidines
- Mechanism of Action Opioid kappa receptor agonists; Sodium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 24 Mar 1997 No-Development-Reported for Arrhythmias in Canada (Unknown route)
- 19 Feb 1995 Preclinical development for Arrhythmias in Canada (Unknown route)